This review covers 2016–2025 evidence on nutraceuticals from plant, animal and microbial sources for atherosclerosis and hypertension. It connects mechanisms such as inflammation, oxidative stress and vascular function with reported clinical endpoints.
Key findings
- The review maps pathways involving inflammation, lipids, endothelial function, oxidative stress and blood-pressure regulation. It also highlights the gap between abundant mechanistic plausibility and the need for stronger clinical outcome evidence.
Why this matters globally
Cardiovascular disease is a major global burden and supplements are widely accessible. Separating mechanistic plausibility from human outcomes can reduce overclaiming and identify priorities for clinical trials.
Thai researcher contribution
Kishoree Krishna Kumaree of Chulalongkorn University contributed to the international review team, adding Thai institutional participation to cardiovascular nutrition evidence synthesis.
Limitations to consider
Products, doses, durations and populations are heterogeneous. Cell or animal mechanisms do not equal human benefit, product quality and drug interactions matter, and the available information cannot support a universal dose.
Verify the original sources
NutrientsRead the original article↗DOI: 10.3390/nu18142226